The development of non-peptide glucagon-like peptide-1 receptor agonist for the treatment of type 2 diabetes
- Ho-Sang MoonAffiliated withResearch Center, Dong-A Pharm. Co., Ltd.
- , Mi-Kyung KimAffiliated withResearch Center, Dong-A Pharm. Co., Ltd.
- , Moon-Ho SonAffiliated withResearch Center, Dong-A Pharm. Co., Ltd. Email author
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Glucagon-like peptide-1 (GLP-1) is the main member of the incretin family and stimulates insulin secretion by binding with its specific receptor on pancreatic β-cells. In addition, GLP-1 exerts broad beneficial effects on the glucose regulation by suppressing food intake and delaying stomach emptying. Now, long acting GLP-1 analogs including exenatide and liraglutide have been approved for the treatment of diabetes mellitus type 2, however long-term injection can limit their use for these chronic patients. In this report, the authors provide a review on the development of non-peptide GLP-1 receptor agonists and introduce a novel agonist DA-15864.
- The development of non-peptide glucagon-like peptide-1 receptor agonist for the treatment of type 2 diabetes
Archives of Pharmacal Research
Volume 34, Issue 7 , pp 1041-1043
- Cover Date
- Print ISSN
- Online ISSN
- Pharmaceutical Society of Korea
- Additional Links
- Industry Sectors